1,093
Views
14
CrossRef citations to date
0
Altmetric
ORIGINAL RESEARCH

Alpha-1 Antitrypsin Deficiency in Canada: Regional Disparities in Diagnosis and Management

, , &

References

  • Fregonese L, Stolk J. Hereditary alpha-1-antitrypsin deficiency and its clinical consequences. Orphanet J Rare Dis 2008; 3:16.
  • Abboud RT, Ford GT, Chapman KR. Alpha1-antitrypsin deficiency: a position statement of the Canadian Thoracic Society. Can Respir J 2001; 8(2):81–88.
  • Campos MA, Wanner A, Zhang G, Sandhaus RA. Trends in the diagnosis of symptomatic patients with alpha1-­antitrypsin deficiency between 1968 and 2003. Chest 2005; 128(3):1179–1186.
  • Richmond RJ, Zellner KM. Alpha1-antitrypsin deficiency: incidence and implications. Dimens Crit Care Nurs 2005; 24(6):255–260.
  • Stoller JK, Fromer L, Brantly M, et al. Primary care diagnosis of alpha-1 antitrypsin deficiency: issues and opportunities. Cleve Clin J Med 2007; 74(12):869–874.
  • Bernspang E, Sveger T, Piitulainen E. Respiratory symptoms and lung function in 30-year-old individuals with alpha-1-­antitrypsin deficiency. Respir Med 2007; 101(9):1971–1976.
  • Sherman CB, Xu X, Speizer FE, et al. Longitudinal lung function decline in subjects with respiratory symptoms. Am Rev Respir Dis 1992; 146(4):855–859.
  • American Thoracic Society/European Respiratory Society Statement: Standards for the Diagnosis and Management of Individuals with Alpha-1 Antitrypsin Deficiency. Amer J Respir Crit Care Med 2003; 168(7):818–900.
  • Marciniuk DD, Hernandez P, Balter M, et al. Alpha1 antitrypsin deficiency targeted testing and augmentation therapy: A Canadian Thoracic Society clincal practice guideline. Can Respir J 2012; 19(2):109–116.
  • Stockley RA, Luisetti M, Miravitlles M, Piitulainen E, Fernandez P. Ongoing research in Europe: Alpha One International Registry (AIR) objectives and development. Euro Respir J 2007; 29(3):582–586.
  • Alpha 1-antitrypsin deficiency: memorandum from a WHO meeting. Bull.World Health Organ 1997; 75(5):397–415.
  • Jones PW, Quirk FH, Baveystock CM, Littlejohns P. A self-complete measure of health status for chronic airflow limitation: The St. George's Respiratory Questionnaire. Am. Rev.Respir. Dis. 1992; 145:1321–1327.
  • Bradi AC, Chapman KR. Update from the Alpha-1 Canadian Registry. Am J Respir Crit Care Med. 2009; 179: A3498.
  • Miravitlles M, Vidal R, Barros-Tizon JC, et al. Usefulness of a national registry of alpha-1-antitrypsin deficiency. The Spanish experience. Respir Med. 1998; 92(10):1181–1187.
  • McElvaney NG, Stoller JK, Buist AS, et al. Baseline characteristics of enrollees in the National Heart, Lung and Blood Institute Registry of alpha 1-antitrypsin deficiency. Alpha 1-Antitrypsin Deficiency Registry Study Group. Chest. 1997; 111(2):394–403.
  • Stoller JK, Sandhaus RA, Turino G, et al. Delay in diagnosis of alpha1-antitrypsin deficiency: a continuing problem. Chest 2005; 128(4):1989–1994.
  • Ad Hoc Committee on Alpha-1-Antitrypsin Replacement Therapy of the Standards Committee CTS. Current status of alpha-1-antitrypsin replacement therapy: recommendations for the management of patients with severe hereditary deficiency. Can Med Asso J 1992; 146:841–844.
  • American Thoracic Society. Guidelines for the approach to the patient with severe hereditary alpha-1-antitrypsin deficiency. Am.Rev.Respir Dis 1989; 140(5):1494–1497.
  • Chapman KR, Stockley RA, Dawkins C, Wilkes MM, Navickis RJ. Augmentation therapy for alpha1 antitrypsin deficiency: a meta-analysis. COPD 2009; 6(3):177–184.
  • Chapman KR, Bradi AC, Paterson D, Navickis RJ, Wilkes MM. Slower lung function decline during augmentation therapy in patients with alpha1-antitrypsin deficiency (A1ATD): results from the Canadian AIR Registry. Am J Respir Crit Care Med 2005;170: 3824.
  • Vreim CE, Wu M, Crystal RG, et al. Survival and FEV 1 decline in individuals with severe deficiency of ‡ 1 -antitrypsin. Amer J Respir Crit Care Med 1998; 158(1):49–59.
  • Campos MA, Alazemi S, Zhang G, et al. Clinical characteristics of subjects with symptoms of alpha1-antitrypsin deficiency older than 60 years. Chest. 2009; 135(3):600–608.
  • Wall M, Moe E, Eisenberg J, et al. Long-term follow-up of a cohort of children with alpha-1-antitrypsin deficiency. J Pediat 1990; 116(2):248–251.
  • Sveger T, Eriksson S. The liver in adolescents with alpha 1-­antitrypsin deficiency. Hepatology 1995; 22(2):514–517.
  • Stockley RA, Luisetti M, Miravitlles M, Piitulainen E, Fernandez P, Alpha One International Registry g. Ongoing research in Europe: Alpha One International Registry (AIR) objectives and development. Eur Respir J. 2007;29(3):
582–586.
  • Stolk J, Stockley RA, Stoel BC, et al. Randomized controlled trial for emphysema with a selective agonist of the gamma type retinoic acid receptor. Eur Respir J 2012.
  • Chapman KR, Burdon JGW, Piitulainen E, et al. IV Alpha1 Antitrypsin (A1AT) preserves lung density in homozygous alpha1 antitrypsin deficiency (A1ATD); A randomized, ­placebo-controlled trial. C20. Late breaking abstracts in clinical trials. American Thoracic Society, International Conference Abstracts 2013; A6069–A6069.
  • Brode SK, Ling SC, Chapman KR. Alpha-1 antitrypsin deficiency: a commonly overlooked cause of lung disease. Canadian Medical Association Journal 2012; 184(12):1365–1371.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.